scispace - formally typeset
Open AccessJournal ArticleDOI

Oxford-AstraZeneca COVID-19 vaccine efficacy.

Maria Deloria Knoll, +1 more
- 09 Jan 2021 - 
- Vol. 397, Iss: 10269, pp 72-74
About
This article is published in The Lancet.The article was published on 2021-01-09 and is currently open access. It has received 518 citations till now. The article focuses on the topics: Vaccine efficacy & Viral Vaccine.

read more

Citations
More filters

COVID-19 Dashboard

Ryan Trimble
Journal ArticleDOI

Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review.

TL;DR: A systematic review of the current literature regarding attitudes and hesitancy to receiving COVID-19 vaccination worldwide was conducted by as discussed by the authors, where the authors identified the consistent socio-demographic groups that were associated with increased hesitance, including women, younger participants, and people who were less educated, had lower income, had no insurance, living in a rural area, and self-identified as a racial/ethnic minority.
Journal ArticleDOI

Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).

TL;DR: In this paper, the authors report a case from Panama with SARS-CoV-2 infection complicated by acute transverse myelitis (ATM) and present a comprehensive clinical review of 43 patients with COVID-19-associated ATM from 21 countries published from March 2020 to January 2021.
Journal ArticleDOI

Role of nanotechnology behind the success of mRNA vaccines for COVID-19.

TL;DR: The emergency use authorization (EUA) by the US-FDA for two mRNA-based vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) has brought hope of addressing the COVID-19 pandemic which has killed more than two million people globally as mentioned in this paper.
Journal ArticleDOI

Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.

TL;DR: The most recent WHO-approved Covid-19 vaccine subtypes, their status and geographical scheduled updates as of 4 May 2021 are discussed, as well as their platforms, trials, limitations and geographical distributions.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.

COVID-19 Dashboard

Ryan Trimble
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Journal ArticleDOI

A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.

TL;DR: A group of international experts, coming together as the International Council on Adult Immunization (ICAI), outlined a high-level roadmap to catalyze action, provide policy guidance, and envision a global adult immunization platform that can be adapted by countries to fit their local contexts.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -